Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Caffeine + curcumin** is a combination of two small molecule compounds: caffeine, a methylxanthine with central nervous system stimulant and anti-inflammatory activity, and curcumin, a polyphenolic phytochemical from turmeric with notable antioxidant, anti-inflammatory, and antipsoriatic effects. In topical nanosponge gel formulation, this combination has shown **augmented anti-psoriatic activity and faster onset of therapeutic effect compared to curcumin alone**, particularly in a mouse model of imiquimod-induced psoriasis. Mechanistically, caffeine acts primarily as a **phosphodiesterase inhibitor, increasing intracellular cAMP concentrations and suppressing inflammatory pathways**, while curcumin modulates phosphorylase kinase activity, various cell signaling pathways, and receptor-mediated responses, contributing to antitumor and anti-inflammatory actions. The combination is under experimental development for dermatological indications, notably psoriasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on caffeine + curcumin.